Movement Alert｜JOINN Rises 5.63% in Regular Trading, CXO Sector Rally Lifts Preclinical CRO Leader

Market Focus08-07

On August 7, JOINN rose 5.63% in regular trading, trading at HKD 25.88/share, with turnover of HKD 109 million. The rally was driven by broad-based strength across the Life Sciences Tools and Services sector.

On the news front, WuXi AppTec previously disclosed its interim results showing H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%. The company also raised its full-year guidance comprehensively, boosting sentiment across the entire CXO complex. Multiple leading CRO/CDMO firms reported significant growth in new order signings during Q1, reinforcing the industry order recovery trend.

Within the Life Sciences Tools and Services sector, Pharmaron rose 9.46%, WuXi XDC gained 8.12%, WuXi Bio advanced 5.94%, and WuXi AppTec climbed 5.68%, reflecting synchronized upward momentum across the board.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102794769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102794769","market":"hk","top_or_hot":-1,"title":"Movement Alert｜JOINN Rises 5.63% in Regular Trading, CXO Sector Rally Lifts Preclinical CRO Leader","media":"Market Focus","content":"<p><p>On August 7, JOINN rose 5.63% in regular trading, trading at HKD 25.88/share, with turnover of HKD 109 million. The rally was driven by broad-based strength across the Life Sciences Tools and Services sector.</p><p>On the news front, WuXi AppTec previously disclosed its interim results showing H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%. The company also raised its full-year guidance comprehensively, boosting sentiment across the entire CXO complex. Multiple leading CRO/CDMO firms reported significant growth in new order signings during Q1, reinforcing the industry order recovery trend.</p><p>Within the Life Sciences Tools and Services sector, Pharmaron rose 9.46%, WuXi XDC gained 8.12%, WuXi Bio advanced 5.94%, and WuXi AppTec climbed 5.68%, reflecting synchronized upward momentum across the board.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜JOINN Rises 5.63% in Regular Trading, CXO Sector Rally Lifts Preclinical CRO Leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜JOINN Rises 5.63% in Regular Trading, CXO Sector Rally Lifts Preclinical CRO Leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 10:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, JOINN rose 5.63% in regular trading, trading at HKD 25.88/share, with turnover of HKD 109 million. The rally was driven by broad-based strength across the Life Sciences Tools and Services sector.</p><p>On the news front, WuXi AppTec previously disclosed its interim results showing H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%. The company also raised its full-year guidance comprehensively, boosting sentiment across the entire CXO complex. Multiple leading CRO/CDMO firms reported significant growth in new order signings during Q1, reinforcing the industry order recovery trend.</p><p>Within the Life Sciences Tools and Services sector, Pharmaron rose 9.46%, WuXi XDC gained 8.12%, WuXi Bio advanced 5.94%, and WuXi AppTec climbed 5.68%, reflecting synchronized upward momentum across the board.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"","article_id":"1102794769","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102794769","pubTimestamp":1786071480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, JOINN rose 5.63% in regular trading, trading at HKD 25.88/share, with turnover of HKD 109 million. The rally was driven by broad-based strength across the Life Sciences Tools and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06127":"昭衍新药"},"translate_title":"走势警报|JOINN 常规交易中上涨 5.63%，CXO 板块反弹提升临床前 CRO 领导者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06127":1},"content_text":"On August 7, JOINN rose 5.63% in regular trading, trading at HKD 25.88/share, with turnover of HKD 109 million. The rally was driven by broad-based strength across the Life Sciences Tools and Services sector.On the news front, WuXi AppTec previously disclosed its interim results showing H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%. The company also raised its full-year guidance comprehensively, boosting sentiment across the entire CXO complex. Multiple leading CRO/CDMO firms reported significant growth in new order signings during Q1, reinforcing the industry order recovery trend.Within the Life Sciences Tools and Services sector, Pharmaron rose 9.46%, WuXi XDC gained 8.12%, WuXi Bio advanced 5.94%, and WuXi AppTec climbed 5.68%, reflecting synchronized upward momentum across the board.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102794769","isCrawlerRequest":true}